The Promise of mRNA Cancer Vaccines: Potential Lives Saved and Economic Value in the U.S.

BackgroundThe U.S. Department of Health and Human Services recently announced plans to curtail investment in messenger RNA (mRNA) vaccine development, despite the central role played by the platform in preventing millions of deaths during the COVID-19 pandemic. Beyond infectious diseases, mRNA vaccines are showing promise in oncology, where early-phase clinical trials report meaningful improvements in overall and recurrence-free survival. Evaluating the potential public health and economic value of these therapies is critical for informing funding decisions. MethodsWe reviewed ongoing mRNA cancer vaccine clinical trials and extracted available survival outcomes. To project potential impact of mRNA vaccination on overall survival, we combined trial-based improvements in survival with incidence and demographic-adjusted survival rates from the Surveillance, Epidemiology, and End Results (SEER) program of National Cancer Institute. A logistic regression framework estimated one- and three-year survival gains. We then applied the Value of a Statistical Life Year (VSLY, $604,000; 3% discount rate) provided by the U.S. Department of Health and Human Services to quantify the economic implications of forgoing mRNA investment. ResultsIn a single annual U.S. cohort of patients newly diagnosed with non-small cell lung cancer, pancreatic cancer, renal cell carcinoma, or melanoma, mRNA vaccination could potentially avert approximately 49,000 deaths within three years of diagnosis. These projected survival gains translate to an estimated economic value of $75 billion. ConclusionsOur findings underscore the substantial public health opportunity provided by mRNA cancer vaccines. Curtailing federal investment risks forfeiting these benefits, while sustained support could accelerate clinical translation and preserve infrastructure essential for future pandemic preparedness.